ANDHealth Achieves Top 10 Most Innovative Company Milestone
Posted: 3 October 2023 ANDHealth, Australia’s leading commercialisation organisation, has today been recognised as one of the top 10 most innovative companies in Australia in the Health Industries category in the Australian Financial Review’s BOSS annual Most Innovative…
Biobank aims to discover new treatments for children with genetic muscle diseases
Posted: 3 October 2023 An Australian first biobank will be established to improve and discover new treatments for children with genetic muscle diseases such as muscular dystrophy. The National Muscle Disease Bio-databank, co-led by Murdoch Children’s Research Institute, Monash…
MNHS researchers awarded $7.5million in NHMRC Centres of Research Excellence funding
Posted: 3 October 2023 The Federal Government has today announced $7.5 million in funding for three National Health and Medical Research Council (NHMRC) Centres of Research Excellence led by Monash Medicine Nursing and Allied Health researchers. The Centres of Research Excellence (CRE)…
Chance discovery shows promise in finding treatment for genetic disorder
Posted: 3 October 2023 Researchers have gained insight into how a toxic protein, known to trigger muscular dystrophy, could be ‘switched off’ – a pre-clinical discovery that could spearhead a treatment for the debilitating disease. Facioscapulohumeral muscular dystrophy…
Latest CRO-67 data shows success in reducing cancer growth
Posted: 3 October 2023 Innovative biotech company Noxopharm Limited (ASX:NOX) announces that further encouraging data from its Chroma™ platform has been presented at the American Association of Cancer Research (AACR) Special Conference on Pancreatic Cancer. The latest in…
DEP irinotecan combination data to be presented at international oncology conference
Posted: 28 September 2023 Starpharma (ASX: SPL, OTCQX: SPHRY) today announces the presentation of data that demonstrate the benefits of combining DEP® irinotecan with other important classes of anti-cancer therapies, including immuno-oncology (IO) agents, in models of human colorectal…
Study finds immune cells in older adults resemble those in newborns and children, but fall short in virus detection
Posted: 28 September 2023 A world-first discovery has revealed special immune cells called ‘killer T cells’ in older adults, directed against influenza viruses, closely resemble those found in newborns and children, but struggle to recognise infected cells –…
Sovereign Capability at Scale
Posted: 28 September 2023 A national team of experts will advance an innovative biopolymer particle-based platform technology to develop vaccine candidates to protect against biowarfare threats including Q Fever, tularaemia, and melioidosis. Health Security Systems Australia (HSSA) is…
VIRALEZE™ UK COVID-19 Clinical Study Completes Recruitment
Posted: 26 September 2023 Starpharma (ASX: SPL, OTCQX: SPHRY) today announces that it has completed recruitment for the post-market clinical study of its broad-spectrum antiviral barrier nasal spray, VIRALEZE™, in patients with COVID-19 in the UK. Recruitment proceeded rapidly…
WEHI discovery leads to clinical trial for rare women’s cancers
Posted: 26 September 2023 An international clinical trial exploring a new way to treat rare and aggressive gynaecological cancers has launched in Melbourne. Based on a WEHI-led discovery, the trial hopes to enhance treatment options for women with…
NEO-BIONICA APPOINTS ULI GOMMEL AS CHIEF TECHNOLOGY OFFICER
Posted: 26 September 2023 Neo-Bionica, a leading innovator in the field of medical device development and manufacturing, is thrilled to announce the appointment of Uli Gommel as its new Chief Technology Officer (CTO). Uli will lead Neo-Bionica’s technology…
Commercial Manufacturing of Eftilagimod Alpha at 2000L Scale Granted Authorization for Clinical Trial Use
Posted: 26 September 2023 Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces the regulatory authorization of eftilagimod alpha (“efti”) manufactured at…
